IHC was useful to demonstrate the role of the SDHA variant but no equivalent assay was available for PALB2. Whole-genome sequencing was not performed due to inadequate DNA from FFPE tissue but may have revealed evidence of the HR deficient mutational signature that is characteristic of PALB2 related cancers. The gene discussed is PALB2; the disease is cancer.